<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371526</url>
  </required_header>
  <id_info>
    <org_study_id>RoSAv1.2:04_10: R&amp;D#5252</org_study_id>
    <secondary_id>2009-018074-56</secondary_id>
    <nct_id>NCT01371526</nct_id>
  </id_info>
  <brief_title>Revival of Stem Cells in Addison's Study</brief_title>
  <acronym>RoSA</acronym>
  <official_title>Revival of Autochthonous Adrenocortical Stem Cells in Autoimmune Addison's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newcastle University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune Addison's disease (AAD) is a rare and debilitating disease in which an autoimmune
      attack progressively destroys the adrenal cortex. Untreated it is universally fatal and
      treated people are absolutely dependent upon steroid medications lifelong, with a consequent
      excess in morbidity and mortality. A key feature of the adrenal cortex is that its cells are
      responsive to changes in circulating adrenocorticotrophic hormone (ACTH) concentration. This
      study aims to regenerate adrenocortical steroidogenic cell function in patients with
      established autoimmune Addison's disease (AAD) by stimulating proliferation and
      differentiation of their progenitor cells, the adrenocortical stem cells (ACSCs) (1,2). Using
      daily subcutaneous ACTH, administered according to two different regimens over 20 weeks, we
      will investigate whether regeneration of adrenal steroidogenic function through revival of
      ACSC activity is a realistic possibility.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak serum Cortisol following ACTH stimulation</measure>
    <time_frame>Tested at 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in QoL</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Adrenal Failure</condition>
  <arm_group>
    <arm_group_label>Synacthen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>depot tetracosactide</intervention_name>
    <description>1mg, 3x weekly by sc injection</description>
    <arm_group_label>Synacthen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established autoimmune adrenal failure for &gt;1yr age 16 to 65

        Exclusion Criteria:

          -  Significant cardio-respiratory, chronic renal or non-autoimmune liver disease;
             malignancy

          -  Asthma, current infectious disease, recent live vaccination, acute psychosis, peptic
             ulcer disease

          -  Pregnancy, breast feeding or plan for pregnancy within 9 months

          -  Known non-autoimmune cause for adrenal failure (haemorrhage, adrenoleukodystrophy
             etc.)

          -  Known hypersensitivity or allergy to Synacthen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon H Pearce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Newcastle University</investigator_affiliation>
    <investigator_full_name>SHS Pearce</investigator_full_name>
    <investigator_title>Professor of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

